<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204659</url>
  </required_header>
  <id_info>
    <org_study_id>64-03</org_study_id>
    <nct_id>NCT00204659</nct_id>
  </id_info>
  <brief_title>Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma</brief_title>
  <official_title>Phase II Study With Rituximab and CHOP in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal treatment of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has not yet
      been defined. In most circumstances, a stomach-conserving approach is favored, but the role
      of radiotherapy is still a matter of debate. Recently, Rituximab along with full-dose CHOP
      chemotherapy has been shown to improve the outcome in elderly patients with nodal DLBCL.
      However, no data are available with such a therapy in patients with PG-DLBCL. Therefore, in
      March 2003, we initiated an ongoing, prospective, multicenter phase II study in patients with
      PG-DLBCL with 6 to 8 cycles of Rituximab (R; 375 mg/m2) plus CHOP-21 in order to evaluate the
      safety and efficacy of this approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>at end of chemo-immunotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 2 and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>after chemo-immunotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Primary Gastric Diffuse-Large B-Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab + CHOP chemotherapy</intervention_name>
    <description>standard Rituximab + CHOP chemo-immunotherapy</description>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Histologically confirmed primary gastric CD20+ DLBCL

          -  Written informed consent

          -  ECOG 0-2

        Exclusion Criteria:

          -  Secondary aggressive Non-Hodgkin`s lymphoma involving the gastric area

          -  HIV positive patients

          -  Severe organ dysfunction

          -  Life expectancy of less than 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfram Brugger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Reutlingen</name>
      <address>
        <city>Reutlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tubingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Clinic</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 17, 2008</last_update_submitted>
  <last_update_submitted_qc>October 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Wolfram Brugger, M.D.</name_title>
    <organization>Schwarzwald-Baar Clinic, Academic Teaching Hospital, Univ. Freiburg</organization>
  </responsible_party>
  <keyword>Rituximab</keyword>
  <keyword>CHOP</keyword>
  <keyword>DLBCL</keyword>
  <keyword>gastric lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

